Summit Therapeutics Inc.SMMTEarnings & Financial Report

Nasdaq · pharmaceutical industry

Bristol-Myers Squibb Company, doing business as Bristol Myers Squibb, is an American multinational pharmaceutical company headquartered in Princeton, New Jersey. The company's primary products are apixaban (Eliquis) for people with atrial fibrillation ; nivolumab (Opdivo), used to treat certain types of cancer ; lenalidomide (Revlimid), used to treat multiple myeloma, smoldering myeloma, and myelodysplastic syndromes ; abatacept (Orencia), used to treat autoimmune diseases such as rheumatoid ...

Revenue

Gross Profit

N/A

Operating Profit

$-58.4M

Net Profit

$-56.3M

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

YoY Growth

N/A

EPS

$-0.08

Summit Therapeutics Inc. Q3 2024 Financial Summary

Summit Therapeutics Inc. reported revenue of $0 for Q3 2024, with a net profit of $-56.3M (N/A margin). Cost of goods sold was N/A, operating expenses totaled N/A.

Key Financial Metrics

Total Revenue	$0
Net Profit	$-56.3M
Gross Margin	N/A
Operating Margin	N/A
Report Period	Q3 2024

Summit Therapeutics Inc. Annual Revenue by Year

Summit Therapeutics Inc. annual revenue history includes year-by-year totals (for example, 2023 revenue was $0).

Year	Annual Revenue
2023	$0
2022	$705.0K

Income Statement

	Q2 2022	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q3 2024
Revenue	$235000	$220000	$0	$0	$0	$0	$0	$0
YoY Growth	312.3%	-83.2%	N/A	N/A	N/A	N/A	N/A	N/A

Balance Sheet

	Q2 2022	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q3 2024
Assets	$95.7M	$155.3M	$664.2M	$254.9M	$237.4M	$218.5M	$202.9M	$502.9M
Liabilities	$44.4M	$22.1M	$537.5M	$121.4M	$117.8M	$119.1M	$125.3M	$64.9M
Equity	$51.3M	$133.2M	$126.7M	$133.5M	$119.6M	$99.4M	$77.7M	$437.9M